Andrea de Bejczy1,2, Elin Löf1,2, Lisa Walther3, Joar Guterstam4, Anders Hammarberg4, Gulber Asanovska5, Johan Franck4, Anders Isaksson3, Bo Söderpalm1,2. 1. Addiction Biology Unit, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. 2. Beroendekliniken, Sahlgrenska University Hospital, Gothenburg, Sweden. 3. Department of Laboratory Medicine, Division of Clinical Chemistry and Pharmacology, Lund University, Skåne University Hospital, Lund, Sweden. 4. Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden. 5. Department of Clinical Alcohol Research, Malmö University Hospital, Lund University, Lund, Sweden.
Abstract
BACKGROUND:Alcohol dependence is a devastating illness affecting a large population, and new pharmacological treatments with good efficacy are greatly needed. One potential candidate is varenicline, a smoking cessation agent with partial agonist action at α4 β2 nicotinic acetylcholine receptors. METHODS:A total of 160 subjects, 30 to 70 years of age, fulfilling DSM-IV criteria for alcohol dependence without any serious physical or mental disorders, were recruited through advertisement at 3 university clinics in Sweden during March 2009 to January 2011. After a 2-week placebo run-in period, subjects received 2 mg varenicline daily (titrated from 0.5 mg during first week) or placebo for 12 weeks in a double-blind manner. RESULTS: The primary outcome was the proportion of heavy drinking days, measured by self-reported alcohol consumption. Primary and secondary outcomes were calculated as a mean over the 10-week steady-state active treatment period. In the primary outcome analysis, no effect of varenicline over placebo was found (p = 0.73 for the intention to treat [ITT] and 0.92 for per protocol [PP]). Secondary outcome analysis found a significant reduction of specific alcohol marker phosphatidylethanol (PEth) in the blood in the varenicline group compared to placebo (p = 0.02 ITT). Craving (p = 0.048 PP) and Alcohol Use Disorders Identification Test (AUDIT) scores (p = 0.015 ITT) were also reduced in the active treatment group. PEth more strongly correlated with self-reported alcohol consumption than carbohydrate-deficient ttransferrin and γ-glutamyl transferase, and correlation coefficients were higher in the varenicline group than in the placebo group for all markers. CONCLUSIONS: Although the results of the main outcome of this study did not support an effect of varenicline in alcohol-dependent individuals, the secondary analyses of PEth, craving and AUDIT score support an effect of varenicline on alcohol consumption. The disclosure of a treatment effect and the lack of a clear placebo effect when using PEth as outcome variable, together with a nonsymmetric bias associated with self-reported data, strongly argue for using the specific biomarker PEth in studies of treatments of alcohol dependence.
RCT Entities:
BACKGROUND:Alcohol dependence is a devastating illness affecting a large population, and new pharmacological treatments with good efficacy are greatly needed. One potential candidate is varenicline, a smoking cessation agent with partial agonist action at α4 β2 nicotinic acetylcholine receptors. METHODS: A total of 160 subjects, 30 to 70 years of age, fulfilling DSM-IV criteria for alcohol dependence without any serious physical or mental disorders, were recruited through advertisement at 3 university clinics in Sweden during March 2009 to January 2011. After a 2-week placebo run-in period, subjects received 2 mg varenicline daily (titrated from 0.5 mg during first week) or placebo for 12 weeks in a double-blind manner. RESULTS: The primary outcome was the proportion of heavy drinking days, measured by self-reported alcohol consumption. Primary and secondary outcomes were calculated as a mean over the 10-week steady-state active treatment period. In the primary outcome analysis, no effect of varenicline over placebo was found (p = 0.73 for the intention to treat [ITT] and 0.92 for per protocol [PP]). Secondary outcome analysis found a significant reduction of specific alcohol marker phosphatidylethanol (PEth) in the blood in the varenicline group compared to placebo (p = 0.02 ITT). Craving (p = 0.048 PP) and Alcohol Use Disorders Identification Test (AUDIT) scores (p = 0.015 ITT) were also reduced in the active treatment group. PEth more strongly correlated with self-reported alcohol consumption than carbohydrate-deficient ttransferrin and γ-glutamyl transferase, and correlation coefficients were higher in the varenicline group than in the placebo group for all markers. CONCLUSIONS: Although the results of the main outcome of this study did not support an effect of varenicline in alcohol-dependent individuals, the secondary analyses of PEth, craving and AUDIT score support an effect of varenicline on alcohol consumption. The disclosure of a treatment effect and the lack of a clear placebo effect when using PEth as outcome variable, together with a nonsymmetric bias associated with self-reported data, strongly argue for using the specific biomarker PEth in studies of treatments of alcohol dependence.
Authors: Ismene L Petrakis; Elizabeth Ralevski; Ralitza Gueorguieva; Stephanie S O'Malley; Albert Arias; Kevin A Sevarino; Jane S Jane; Erin O'Brien; John H Krystal Journal: Addiction Date: 2017-10-12 Impact factor: 6.526
Authors: Yan Wang; Xinguang Chen; Judith A Hahn; Babette Brumback; Zhi Zhou; Maria J Miguez; Robert L Cook Journal: Alcohol Clin Exp Res Date: 2017-12-05 Impact factor: 3.455
Authors: Robert Miranda; Stephanie S O'Malley; Hayley Treloar Padovano; Ran Wu; Daniel E Falk; Megan L Ryan; Joanne B Fertig; Thomas H Chun; Srinivas B Muvvala; Raye Z Litten Journal: Alcohol Clin Exp Res Date: 2020-05-25 Impact factor: 3.455
Authors: Krysten W Bold; Allen Zweben; Lisa M Fucito; Mary E Piepmeier; Srinivas Muvvala; Ran Wu; Ralitza Gueorguieva; Stephanie S O'Malley Journal: Alcohol Clin Exp Res Date: 2019-03-21 Impact factor: 3.455